UpSurgeOn announced the closing of a €5 million investment round to accelerate its global expansion and advance its hybrid surgical training technologies. The funding round was led by CDP Venture Capital, with participation from SIMEST, Deep Blue Ventures, Azimut Libera Impresa, and FBH S.p.A. This follows a previous €3 million round completed in 2022, bringing total institutional funding to over €8 million.
Based in Milan, the company develops high-fidelity simulation platforms that combine physical anatomical models, virtual reality, and digital tools to enhance surgical skills. Its solutions are already commercialized in more than 110 countries and are used across disciplines, including neurosurgery, plastic surgery, orthopedics, and otolaryngology.
The company said the new capital will be used to expand internationally, enhance its proprietary simulation platforms across additional surgical specialties, and accelerate research and development focused on psychomotor training and objective performance metrics for surgeons. The broader goal is to improve surgical training standards, reduce learning curves, and ultimately enhance patient safety.
UpSurgeOn highlighted that its hybrid approach integrates immersive digital environments with hyper-realistic physical simulators, enabling standardized and measurable training outcomes. The company collaborates with global medtech firms and scientific institutions, aiming to democratize access to high-quality surgical education worldwide.
KEY QUOTES:
“We are extremely proud and motivated by this important round and honored to collaborate with highly visionary partners. We will continue to expand our global presence while maintaining a clear focus on the concrete needs of surgery: UpSurgeOn stems from the ability to listen to a complex ecosystem, without ever forgetting that the ultimate goal of our work is the patient’s well-being.”
Federico Nicolosi, CEO and Founder, UpSurgeOn
“Investing in UpSurgeOn means supporting an exceptional team with a unique blend of cross-functional skills. We are convinced that this platform can have a tangible impact on patient safety worldwide: having increasingly prepared surgeons means improving people’s lives. In a sector where access to quality training is still deeply unequal depending on geographical areas, UpSurgeOn has the potential to democratize surgical excellence on a global scale.”
Mario Scuderi, Head Of The Evoluzione Fund, CDP Venture Capital
“UpSurgeOn represents a concrete example of how deep tech can transform scientific research into high-impact industrial applications. The ability to integrate physical simulation, digital platforms, and virtual reality into a single technological ecosystem opens new perspectives in advanced surgical training. With Deep Blue Ventures, we support entrepreneurial entities that do not merely innovate a product, but redefine industry standards and infrastructures: in the case of UpSurgeOn, contributing to improving the quality of medical training and, ultimately, patient safety on a global scale.”
Domenico Nesci, CEO, Deep Ocean Capital SGR And Partner, Deep Blue Ventures
“As Azimut Venture Capital, we are thrilled to support UpSurgeOn on its journey to revolutionize medical training. Their advanced simulation technology aims to bridge the gap between theory and practice, offering surgeons a hyper-realistic environment. We believe that Federico Nicolosi, CEO and co-founder, also in his capacity as a former surgeon, is the right person to leverage the development of this technology to support patients.”
Guido Bocchio, Head Of Venture Capital, Azimut Libera Impresa SGR
“With this investment, SIMEST supports the international expansion path of UpSurgeOn, an Italian deep-tech reality bringing innovative solutions for advanced surgical training to global markets. The technological approach developed by the company, integrating hybrid simulation, physical models, and digital platforms, responds to a growing international demand for training tools that are increasingly effective, accessible, and based on objective metrics. Operations like this contribute to strengthening the presence of highly technological Italian companies in major global scientific and medical ecosystems, favoring the diffusion of Made in Italy expertise and innovation.”
Vera Veri, Chief Investment Officer, SIMEST
